Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | DDX3X | O00571 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.50 |
| ▸ | BAZ1A | Q9NRL2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457807 | 0.88 | CFTR (0.55) | CFTRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5460669 | 0.86 | PDE4B (0.58) | PDE4BCFTRMEN1KMT2AMAPT | |
| SCHEMBL5467205 | 0.85 | CFTR (0.56) | CFTRMEN1KMT2AMAPTHTT | |
| SCHEMBL5454365 | 0.84 | CFTR (0.55) | CFTRMEN1KMT2AMAPTHTT | |
| SCHEMBL5457654 | 0.84 | CFTR (0.55) | CFTRMEN1KMT2AMAPTHTT | |
| SCHEMBL5448351 | 0.84 | CFTR (0.55) | CFTRMEN1KMT2AMAPTHTT | |
| SCHEMBL5451652 | 0.84 | CFTR (0.60) | CFTRMEN1KMT2AMAPTHTT | |
| SCHEMBL5455947 | 0.84 | MEN1 (0.65) | CFTRMEN1KMT2AMAPTNPC1 | |
| SCHEMBL5466862 | 0.83 | CFTR (0.57) | CFTRMEN1KMT2AMAPTHTT | |
| SCHEMBL5457889 | 0.83 | CFTR (0.55) | PDE4BCFTRMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | PDE4B 1387/4885CFTR 2030/4885MEN1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.